The Immune Response Corporation Forms New Scientific Advisory Board for Multiple Sclerosis; Prestigious Board to Guide Research and Development of NeuroVax(TM)

"We are honored to have six of the leading minds in MS researchworking with us to guide the development of NeuroVax(TM)," said Dr.Joseph O'Neill, Chief Executive Officer and President of The ImmuneResponse Corporation. "Our clinical findings indicate thatNeuroVax(TM) induces strong, disease-specific immune responses inessentially all the MS patients treated. We are eager to continue withadditional Phase II studies and will launch a 300-patient trial laterthis year in Eastern Europe and the United States that will test theclinical benefit of NeuroVax(TM) by assessing its effect on MRI andrelapse rates."

New data indicates that an important part of the strongdisease-specific immune response induced by NeuroVax(TM) is thestimulation of FOXP3+ Regulatory T-cells. This exciting approach couldplay an important role in the treatment of MS and other autoimmunediseases, such as rheumatoid arthritis, psoriasis and Crohn's disease.

The Scientific Advisory Board guiding the development ofNeuroVax(TM) will consist of six members:
Dr. Jack Antel is a professor in the Department of Neurology and
Neurosurgery at McGill University. He is Co-Director of the
Neuroinflammation Training Program sponsored by the Canadian Institute
of Health Research (CIHR). In 2005, Dr. Antel received the National MS
Society/American Academy of Neurology John Dystel Prize for MS
Research. He is also an associate member of McGill's Department of
Microbiology and Immunology and Coordinator of the MS Program at the
Montreal Neurologic Institute.

Dr. Dennis Bourdette is the Director of the MS Center of Oregon
and Chair for the Department of Neurology at Oregon Health and Science
University (OHSU), where he has been a faculty member since 1983. He
is also a staff neurologist at the Portland Veterans Affairs Medical
Center. Dr. Bourdette has published numerous articles on MS and is
listed in the Best Doctors in America.

Professor Giancarlo Comi is the Director of the Department of
Neurology and Clinical Neurophysiology at San Raffaele Hospital in
Milan, Italy. He is a professor of Neurology at the University
Vita-Salute San Raffaele and has chaired its graduate school in
neurology since 2001. His fields of interest are the study of the
natural history, research and validation of new therapies in MS.
Professor Comi has authored or co-authored more than 400 articles in
peer-reviewed journals and edited six books.

Professor Krzysztof W. Selmaj is the Chairman of the Department of
Neurology at the Medical University in Lodz, Poland, and serves as the
Chairman of the European Federation of Neurology. He has received
several honors and awards, including the Polish Academy of Science
Sniadecki Award and the Polish Science Foundation Award. Professor
Selmaj has authored numerous articles about neurology and MS and is on
the editorial boards of the Journal of Neuroimmunology and European
Journal of Neurology.

Dr. Arthur Vandenbark is a senior research career scientist at the
Portland Veterans Affairs Medical Center, and a professor in the
Departments of Neurology and Molecular Microbiology and Immunology at
OHSU. An inventor and pioneer of the TCR peptide vaccination approach
for MS, Dr. Vandenbark is the recipient of the Javits Neuroscience
Investigator Award. He has published numerous articles in the area of
MS and its animal models.

Dr. Jerry S. Wolinsky directs the Multiple Sclerosis Research
Group and the Magnetic Resonance Imaging Analysis Center at the
Graduate School of Biomedical Sciences at the University of Texas
Health Science Center at Houston. He chairs the Research Programs
Advisory Committee of the National MS Society and is the Chair of the
Americas Committee for Treatment and Research in MS. Dr. Wolinsky is
an associate editor of ACP Medicine and on the editorial board of
Multiple Sclerosis: Clinical and Laboratory Research. He is recognized
in The Best Doctors in America and America's Top Doctors.

Forming a Scientific Advisory Board for NeuroVax(TM) is part of anew strategic initiative to leverage The Immune Response Corporation'score immune-based technology for autoimmune and infectious diseases.Specifically, this strategy will focus on the accelerated developmentof the Company's most promising immune-based therapies currently inclinical trials, NeuroVax(TM) for MS and IR103 for humanimmunodeficiency virus (HIV).

About Multiple Sclerosis

MS is an autoimmune disease in which the immune system mistakenlyattacks normal tissues of the central nervous system. It afflictsapproximately 400,000 people in the United States and more than 2.5million worldwide (source: National MS Society). The disease is causedby activation of a specific subset of the patient's own white bloodcells, pathogenic T-cells, which then attack a fatty tissue calledmyelin that surrounds and protects nerve fibers and creates scarring(sclerosis) that interferes with the normal transmission of nerveimpulses. This damage, in turn, leads to a variety of chronic andhighly individual and unpredictable neurological symptoms, rangingfrom movement and balance problems to vision impairment.

Autoimmune diseases such as MS may result from the failure ofnormal immune regulatory mechanisms to prevent proliferation ofpathogenic T-cells. Specifically, Immune Response Corporation'sresearch indicates that MS patients have diminished levels of FOXP3message and protein expression levels in peripheral T-cells. Thisobservation is the first to link a defect in functional peripheralimmunoregulation to an established genetic marker, FOXP3, whichpreviously has been shown to be involved in maintaining immunetolerance and repressing the development of autoimmune diseases suchas MS.

About The Immune Response Corporation

The Immune Response Corporation (OTCBB:IMNR) is animmuno-pharmaceutical company focused on developing products to treatautoimmune and infectious diseases. The Company's lead immune-basedtherapeutic product candidates are NeuroVax(TM) for the treatment ofMS and IR103 for the treatment of HIV infection. Both of thesetherapies are in Phase II clinical development and are designed tostimulate pathogen-specific immune responses aimed at slowing orhalting the rate of disease progression.

NeuroVax(TM), which is based on the Company's patented T-cellreceptor (TCR) peptide technology, has shown potential clinical valuein the treatment of relapsing forms of MS. NeuroVax(TM) has been shownto stimulate strong, disease-specific, cell-mediated immunity innearly all patients treated and appears to work by enhancing levels ofFOXP3+ Treg cells that are able to down regulate the activity ofpathogenic T-cells that cause MS. Increasing scientific findings haveassociated diminished levels of FOXP3+ Treg cell responses with thepathogenesis and progression of MS and other autoimmune diseases suchas rheumatoid arthritis (RA), psoriasis and Crohn's disease. Inaddition to MS, the Company has open Investigational New DrugApplications (IND) with the FDA for clinical evaluation of TCRpeptide-based immune-based therapies for RA and psoriasis.

IR103 is based on the Company's patented whole-inactivated virustechnology, co-invented by Dr. Jonas Salk and indicated to be safe andimmunogenic in extensive clinical studies of REMUNE(R), the Company'sfirst-generation HIV product candidate. IR103 is a more potentformulation that combines its whole-inactivated antigen with asynthetic Toll-like receptor (TLR-9) agonist to create enhancedHIV-specific immune responses. The Company is currently testing IR103in two Phase II clinical studies as a first-line treatment fordrug-naive, HIV-infected individuals not yet eligible forantiretroviral therapy according to current medical guidelines.

NeuroVax(TM) and IR103 are in clinical development by The ImmuneResponse Corporation and are not approved by any regulatory agenciesin any country at this time. Please visit The Immune ResponseCorporation at www.imnr.com for more information.

This news release contains forward-looking statements.Forward-looking statements are often signaled by forms of words suchas "should," "could," "will," "might," "plan," "projection,""forecast," "expect," "guidance," "potential" and "developing."

Actual results could vary materially from those expected due to avariety of risk factors, including whether the Company will continueas a going concern and successfully raise proceeds from financingactivities sufficient to fund operations and additional clinicaltrials of its product candidates, the uncertainty of successfulcompletion of any such clinical trials, the fact that the Company hasnot succeeded in commercializing any drug, the risk that its productcandidates might not prove to be effective as either a therapeutic orpreventive vaccine, whether future trials will be conducted, andwhether the results of such trials will coincide with the results ofits product candidates in preclinical trials and/or earlier clinicaltrials. A more extensive set of risks is set forth in The ImmuneResponse Corporation's SEC filings, including, but not limited to, itsAnnual Report on Form 10-K for the year ended December 31, 2005. TheCompany undertakes no obligation to update the results of theseforward-looking statements to reflect events or circumstances aftertoday or to reflect the occurrence of unanticipated events.

NeuroVax(TM) is a trademark of The Immune Response Corporation.REMUNE(R) is a registered trademark of The Immune ResponseCorporation.